These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 29157068

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.
    Greenberg DP, Robertson CA, Talbot HK, Decker MD.
    Hum Vaccin Immunother; 2017 Sep 02; 13(9):2058-2064. PubMed ID: 28700265
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea.
    Choi WS, Noh JY, Lee J, Choi JY, Lee JS, Kim MS, Kim HS, Bang J, Lavis N, Kim WJ.
    Hum Vaccin Immunother; 2018 Mar 04; 14(3):587-592. PubMed ID: 28933625
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study.
    Statler VA, Albano FR, Airey J, Sawlwin DC, Graves Jones A, Matassa V, Heijnen E, Edelman J, Marshall GS.
    Vaccine; 2019 Jan 07; 37(2):343-351. PubMed ID: 30057283
    [Abstract] [Full Text] [Related]

  • 8. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults.
    Gorse GJ, Falsey AR, Ozol-Godfrey A, Landolfi V, Tsang PH.
    Vaccine; 2015 Feb 25; 33(9):1151-9. PubMed ID: 25613721
    [Abstract] [Full Text] [Related]

  • 9. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study.
    Pepin S, Szymanski H, Rochín Kobashi IA, Villagomez Martinez S, González Zamora JF, Brzostek J, Huang LM, Chiu CH, Chen PY, Ahonen A, Forstén A, Seppä I, Quiroz RF, Korhonen T, Rivas E, Monfredo C, Hutagalung Y, Menezes J, Vesikari T.
    Hum Vaccin Immunother; 2016 Dec 25; 12(12):3072-3078. PubMed ID: 27565435
    [Abstract] [Full Text] [Related]

  • 10. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, Santos J, Montalban MC, de Looze FJ, Eizenberg P, Hall S, Dupuy M, Hutagalung Y, Pépin S, Saville M.
    Vaccine; 2015 May 15; 33(21):2485-92. PubMed ID: 25843270
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine.
    Montalban C, Montellano MB, Santos J, Lavis N.
    Hum Vaccin Immunother; 2018 Mar 04; 14(3):593-595. PubMed ID: 28933626
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
    Treanor JT, Albano FR, Sawlwin DC, Graves Jones A, Airey J, Formica N, Matassa V, Leong J.
    Vaccine; 2017 Apr 04; 35(15):1856-1864. PubMed ID: 28302411
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries.
    Haugh M, Gresset-Bourgeois V, Macabeo B, Woods A, Samson SI.
    Expert Rev Vaccines; 2017 Jun 04; 16(6):545-564. PubMed ID: 28460594
    [Abstract] [Full Text] [Related]

  • 17. Inactivated quadrivalent split-virus seasonal influenza vaccine (Fluarix® quadrivalent): a review of its use in the prevention of disease caused by influenza A and B.
    McKeage K.
    Drugs; 2013 Sep 04; 73(14):1587-94. PubMed ID: 24022123
    [Abstract] [Full Text] [Related]

  • 18. Evidence update: GlaxoSmithKline's inactivated quadrivalent influenza vaccines.
    Bekkat-Berkani R, Ray R, Jain VK, Chandrasekaran V, Innis BL.
    Expert Rev Vaccines; 2016 Sep 04; 15(2):201-14. PubMed ID: 26641539
    [Abstract] [Full Text] [Related]

  • 19. High-Dose Inactivated Influenza Vaccine Quadrivalent for Older Adults.
    Chahine EB.
    Ann Pharmacother; 2021 Jan 04; 55(1):89-97. PubMed ID: 32578447
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.